Evolve CSO presenting at the Microbiome Congress: Asia

Evolve BioSystems is pleased to announce that our Chief Scientific Officer, Dr. David Kyle, will be speaking at the 4th Microbiome R&D and Business Collaboration Congress: Asia, to be held on March 5 – 6, 2018 in Singapore.

Dr. Kyle will be presenting our latest research on the infant gut microbiome, in a talk titled "From Dysbiosis to Recovery in the Infant Gut Microbiome."

The 4th Microbiome R&D and Business Collaboration Congress: Asia is focused on bringing together leaders in microbiota research, probiotics, health and disease. Building on the success of the meetings in the previous three years, the event will bring well over 200 attendees from across the world to Singapore.

For more details on the event, click here

Evolve BioSystems Contact
Dr. Tracy Shafizadeh
Director, Scientific Communications
tshafizadeh@evolvebiosystems.com

About Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering.  In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.

Tracy Shafizadeh